Systematic review and meta-analysis on interventions for radiation dermatitis prevention and management: an overview of the methods.

Guidelines Meta-analysis Methods Oncodermatology Radiation dermatitis Systematic review

Journal

Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer
ISSN: 1433-7339
Titre abrégé: Support Care Cancer
Pays: Germany
ID NLM: 9302957

Informations de publication

Date de publication:
13 Apr 2023
Historique:
received: 23 11 2022
accepted: 26 03 2023
medline: 17 4 2023
entrez: 13 4 2023
pubmed: 14 4 2023
Statut: epublish

Résumé

Over several decades, research on the prevention and management of acute radiation dermatitis (RD) has continued to emerge, yet there remains no "gold standard" treatment for RD care. Recent guidelines on RD prevention and management were published in 2022 by the Oncodermatology Study Group of the Multinational Association of Supportive Care in Cancer (MASCC). As part of this guideline process, a collaborative effort was undertaken by international RD experts to quantitatively compare commonly studied RD skin interventions through meta-analyses and discern superiority of interventional treatments over another intervention, standard-of-care, or placebo in RD prevention and management. This paper summarizes the materials and methodology used in a set of meta-analysis studies that supplement the 2022 MASCC Clinical Practice Guidelines on RD Prevention and Management.

Identifiants

pubmed: 37052753
doi: 10.1007/s00520-023-07707-5
pii: 10.1007/s00520-023-07707-5
doi:

Types de publication

Meta-Analysis Systematic Review Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

261

Informations de copyright

© 2023. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.

Références

Singh M, Alavi A, Wong R, Akita S (2016) Radiodermatitis: a review of our current understanding. Am J Clin Dermatol 17(3):277–292. https://doi.org/10.1007/s40257-016-0186-4
doi: 10.1007/s40257-016-0186-4 pubmed: 27021652
McQuestion M, Cashell A (2020) A qualitative descriptive study of patients’ experiences of a radiation skin reaction associated with treatment for a head and neck cancer. Can Oncol Nurs J 30(4):287–292
doi: 10.5737/23688076304287292 pubmed: 33165369 pmcid: 7597777
Chen M-F, Chen W-C, Lai C-H, Hung C-H, Liu K-C, Cheng Y-H (2010) Predictive factors of radiation-induced skin toxicity in breast cancer patients. BMC Cancer 10:508. https://doi.org/10.1186/1471-2407-10-508
doi: 10.1186/1471-2407-10-508 pubmed: 20860847 pmcid: 2955039
Wong RKS et al (2013) Clinical practice guidelines for the prevention and treatment of acute and late radiation reactions from the MASCC Skin Toxicity Study Group. Support Care Cancer Off J Multinatl Assoc Support Care Cancer 21(10):2933–2948. https://doi.org/10.1007/s00520-013-1896-2
doi: 10.1007/s00520-013-1896-2
Gosselin T et al (2020) ONS Guidelines™ for cancer treatment-related radiodermatitis. Oncol Nurs Forum 47(6):654–670. https://doi.org/10.1188/20.ONF.654-670
doi: 10.1188/20.ONF.654-670 pubmed: 33063779
Multinational Association of Supportive Care in Cancer (2018) “MASCC guidelines policy: recommendations for MASCC guideline construction and the endorsement of externally generated guidelines”
Behroozian T, Goldshtein D, Ryan Wolf J et al (2023) MASCC clinical practice guidelines for the prevention and management of acute radiation dermatitis: part 1) systematic review. eClinicalMedicine 101886. https://doi.org/10.1016/j.eclinm.2023.101886
Behroozian T, Bonomo P, Patel P et al (2023) Multinational Association of Supportive Care in Cancer (MASCC) clinical practice guidelines for the prevention and management of acute radiation dermatitis: international Delphi consensus-based recommendations. Lancet Oncol 24(4):e172–e185. https://doi.org/10.1016/S1470-2045(23)00067-0
Hadorn DC, Baker D, Hodges JS, Hicks N (1996) Rating the quality of evidence for clinical practice guidelines. J Clin Epidemiol 49(7):749–754. https://doi.org/10.1016/0895-4356(96)00019-4
doi: 10.1016/0895-4356(96)00019-4 pubmed: 8691224
“What is GRADE? | BMJ Best Practice.” https://bestpractice.bmj.com/info/toolkit/learn-ebm/what-is-grade/ (accessed Jan. 28, 2022).
Sterne JAC et al (2019) RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ 366:l4898. https://doi.org/10.1136/bmj.l4898
doi: 10.1136/bmj.l4898 pubmed: 31462531

Auteurs

Tara Behroozian (T)

Michael G. DeGroote School of Medicine, McMaster University, Hamilton, ON, Canada. Tara.Behroozian@medportal.ca.

Saverio Caini (S)

Cancer Risk Factors and Lifestyle Epidemiology Unit, Institute for Cancer Research, Prevention and Clinical Network (ISPO), Florence, Italy.

Corina van den Hurk (C)

Netherlands Comprehensive Cancer Organisation, Utrecht, The Netherlands.

Pierluigi Bonomo (P)

Department of Radiation Oncology, Azienda Ospedaliero-Universitaria Careggi, Florence, Italy.

Edward Chow (E)

Department of Radiation Oncology, University of Toronto, Toronto, ON, Canada.

Julie Ryan Wolf (JR)

Department of Dermatology, University of Rochester Medical Centre, Rochester, NY, USA.
Department of Radiation Oncology, University of Rochester Medical Centre, Rochester, NY, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH